Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neurilemmoma 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × antineoplaston AS 2-1 × Clear all
NCT00003452 2017-09-28

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Burzynski Research Institute

Phase 2 Terminated
4 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡